LBLiam R. Brunham

Liam R. Brunham

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Liam R. Brunham has a total of 552 co-authors. Here are the top co-authors by number of shared publications:

  • G.B. John Mancini

    Centre for Cardiovascular Innovation, Dilawri Cardiovascular Institute, University of British Columbia, Vancouver, Canada (John Mancini)

    15 shared publications
  • Gordon A. Francis

    Departments of Medicine and Medical Genetics, Centre for Heart Lung Innovation, Providence Research, University of British Columbia, Vancouver, Canada (Cermakova, Wan, Francis, and Brunham)

    15 shared publications
  • Lubomira Cermakova

    Departments of Medicine and Medical Genetics, Centre for Heart Lung Innovation, Providence Research, University of British Columbia, Vancouver, Canada (Cermakova, Wan, Francis, and Brunham)

    15 shared publications
  • Mark Trinder

    Centre for Heart Lung Innovation

    15 shared publications
  • Robert Alexander Hegele

    Department of Medicine and Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, Canada

    12 shared publications
  • Mark Trinder

    Department of Pathology and Laboratory Medicine University of British Columbia Vancouver British Columbia Canada

    10 shared publications

Latest Publications

  • Open Access

    Temporal changes in lipoprotein(a) following acute coronary syndrome: a systematic review and meta-analysis

    by Arveen Shokravi, Jayant Seth, Joshua Yoon, G B John Mancini, Ricky D Turgeon, Liam R Brunham, Christopher B Fordyce

    Aims: Lipoprotein(a) [Lp(a)] is a genetically determined cardiovascular risk factor generally considered stable over an individual’s lifetime. Acute coronary syndrome (ACS) may transiently alter Lp(a) concentrations, complicating interpretation. We systematically evaluated temporal changes in Lp(a) following ACS. Methods and results: This PRISMA 2020-guided systematic review searched MEDLINE and Embase from database inception to February 2026. Eligible studies reported serial Lp(a) measurements at two or more time points after an index ACS event. Exploratory random-effects meta-analysis of percent change in mean Lp(a) was performed. Of 3811 records, 16 studies comprising 1396 patients met the inclusion criteria. Lp(a) demonstrated a dynamic post-ACS trajectory. Using initial post-ACS measurements as the reference, pooled percent change in mean Lp(a) was non-significant at 24 h post-ACS (+2.5%, 95% confidence interval [CI] −6.8 to 11.7; P = 0.602). Lp(a) was significantly higher at 7–14 days (+44.0%, 95% CI 4.0–84.1; P = 0.031), 1 month (+28.3%, 95% CI 2.7–54.0; P = 0.030), and 3–6 months (+22.2%, 95% CI 2.4–42.0; P = 0.028). Across two studies, absolute Lp(a) increases >25 nmol/L occurred in 17% and 22% of patients by 3 and 6 months, respectively. Conclusion: Lp(a) is not static post-ACS. Early post-ACS measurements may underestimate long-term concentrations and risk. Repeat measurement weeks to months later is most informative when initial post-ACS Lp(a) values are near clinical decision thresholds or would influence eligibility for emerging Lp(a)-lowering therapies.

  • Predictors of aortic stenosis in homozygous familial hypercholesterolemia: A study from the Canadian HoFH registry

    by Martine Paquette, Armen Erzingatzian, Isabelle Ruel, Zobaida Al-Baldawi, Leslie Brown, Mark H. Sherman, Nathalie Laflamme, Jean Bergeron, Patrick Couture, Diane Brisson, et al.

  • Open Access

    Opportunistic Genetic Testing for Familial Hypercholesterolemia in Premature Acute Coronary Syndrome

    by Nicol Vaizman, Lubomira Cermakova, Matthew Cooper, Adam I. Kramer, Kyle Hui, Linda M. Jackson, Thomas M. Roston, G.B. John Mancini, Christopher B. Fordyce, Iulia Iatan, et al.


  • Open Access

    Rationale and Design of the Canadian Lipoprotein(a) Registry

    by Adam I. Kramer, Husam Abdel-Qadir, Beth L. Abramson, Alexis Baass, Jean Bergeron, Apoorva Bollu, Lubomira Cermakova, Patrick Couture, Christopher B. Fordyce, Milan Gupta, et al.

  • The Expanding Oral Options for LDL Cholesterol Management

    by Liam R. Brunham, Michael D. Shapiro, Vijay Nambi


  • Top Cited Papers

    In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia

    by Scott B. Vafai, Jörg Täubel, Thomas Ashdown, Riyaz S. Patel, Sadaf Diamondali, Jaimini Cegla, Handrean Soran, Bilal Bashir, Alexander Abitbol, Daniel Gaudet, et al.

    Persons carrying loss-of-function variants of proprotein convertase subtilisin-kexin type 9 (PCSK9) have reduced levels of low-density lipoprotein (LDL) cholesterol and fewer atherosclerotic cardiovascular disease events than persons without such variants. VERVE-102 is an investigational base-editing therapy designed to durably inactivate PCSK9 in the liver. In this phase 1, open-label, single-ascending-dose study, we administered one intravenous infusion of VERVE-102 at one of six doses (ranging from 0.3 to 1.0 mg of total RNA per kilogram of body weight [mg per kilogram]) to adults with heterozygous familial hypercholesterolemia or premature coronary artery disease. VERVE-102 consists of a messenger RNA encoding an adenine base-editor protein and a guide RNA targeting PCSK9, which are encapsulated in a lipid nanoparticle incorporating N-acetylgalactosamine. The objectives were to assess safety and changes in blood PCSK9 protein and LDL cholesterol levels. A total of 35 participants across the six dose cohorts received VERVE-102 and had at least 28 days of follow-up. No dose-limiting toxic effects occurred. Mild-to-moderate infusion-related reactions and transient elevations in alanine aminotransferase levels were observed. Aspiration pneumonitis occurred in a participant with gastroesophageal reflux disease. Dose-dependent mean reductions in the PCSK9 level ranged from 51% at the 0.3-mg-per-kilogram dose to 88% at the 1.0-mg-per-kilogram dose. Corresponding reductions in the LDL cholesterol level ranged from 9% at the 0.3-mg-per-kilogram dose to 62% at the 1.0-mg-per-kilogram dose, with an absolute reduction of 78 mg per deciliter at the highest dose. Reductions appeared to be durable throughout follow-up, which was at least 1 year in 15 participants. One dose of VERVE-102 led to dose-dependent, substantial, and sustained reductions in PCSK9 and LDL cholesterol levels. (Funded by Verve Therapeutics; ClinicalTrials.gov number, NCT06164730.).


  • Open Access

    Temporal Trends in Lipid‐Lowering Therapy Use and Adherence in Patients With Premature Coronary Artery Disease

    by Diana N. Vikulova, Danielle Pinheiro‐Muller, Simon N. Pimstone, Liam R. Brunham

    Background: Patients with premature coronary artery disease (CAD) have high rates of recurrent events and death. Information on long‐term adherence to lipid‐lowering therapy (LLT) and trends in medication‐taking behavior in premature CAD is limited. We assessed temporal trends in LLT, factors associated with adherence to LLT, and the consequences of low adherence in a longitudinal cohort of patients with premature CAD. Methods: Using a cardiovascular registry and administrative databases, we analyzed temporal changes in rates and predictors of adherence to LLT as well as the association between adherence and cardiovascular outcomes in patients with premature obstructive CAD from 2000 to 2017. Results: Among 11 411 patients with premature CAD, 27.6% were women and the mean±SD age was 46.1±5.05 years. The proportion with good first‐year adherence to LLT increased from 54.9% to 71.4% ( P P P <0.001). More severe presentation, revascularization at presentation, absence of chronic kidney disease, and nonsmoking were consistently associated with better adherence across the study time frame. Rural residence, female sex, and substance use disorder were associated with poor adherence only in later years. Good adherence was associated with a lower risk of cardiovascular outcomes, including death (hazard ratio [HR], 0.45 [95% CI, 0.39–0.55]) and myocardial infarction (HR, 0.53 [95% CI, 0.45–0.63]). Conclusions: Use of high‐intensity LLT and short‐term adherence are improving in patients with premature CAD, but different strategies are needed to increase long‐term adherence to prevent recurrent cardiovascular events.

  • Open Access

    Global survey of genetic testing methods for familial hypercholesterolaemia: a study and recommendations from the European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration registry

    by Joana Rita Chora, Irene Karungi, Amany Elshorbagy, Christophe A T Stevens, Antonio J Vallejo-Vaz, Kanika I Dharmayat, Marianne Abifadel, Carlos A Aguilar-Salinas, Khalid F Alhabib, Wael Almahmeed, et al.

    Aims: Familial hypercholesterolaemia (FH), primarily caused by pathogenic LDLR, APOB, or PCSK9 variants, results in elevated LDL cholesterol and increased cardiovascular risk. Genetic testing offers the definitive diagnosis, yet global approaches to FH genetic testing remain unstandardized. We investigate current testing practices worldwide and provide relevant recommendations. Methods and results: A survey was distributed to national lead investigators of 68 countries in the Familial Hypercholesterolaemia Studies Collaboration, assessing referral criteria, assay methodologies, target genes, and pathogenicity interpretation methods. National lead investigators from centres in 55/68 countries (81%) responded, spanning Africa (n = 2), Americas (n = 6), Asia (n = 20), Europe (n = 26), and Oceania (n = 1). Dutch Lipid Clinic Network (DLCN) scores were the most common reason for referral to genetic testing (adults, 72%; children, 57%). Simon–Broome and Make Early Diagnosis to Prevent Early Death (MEDPED) criteria were reported only by centres from high-income countries (adults, 7% and 2%; children, 12% and 2%). Methods for testing in index vs. non-index cases were significantly different (P < 0.001). Next-generation sequencing (NGS) was the predominant assay method for index cases (62%), while Sanger sequencing was favoured for non-index (71%). However, these testing techniques did not differ between centres from high- and non-high-income countries for index cases (P = 0.74) and non-index cases (P = 0.49). Copy-number variants (CNVs) were assessed by 65% of centres, with most integrating CNV analysis into NGS platforms (86%) and others (14%) using multiplex ligation-dependent probe amplification (MLPA) or microarrays. Screening encompassed LDLR (100%), APOB (97%), PCSK9 (95%), and other genes. Most centres (96%) incorporated pathogenicity interpretation into their reports, adhering largely to American College of Medical Genetics and Genomics guidelines. Conclusion: Familial hypercholesterolaemia genetic testing practices vary widely across countries surveyed, emphasizing the need for global standardization to enhance accuracy and comparability of FH diagnoses worldwide. We suggest that genetic testing should include the three FH-causing genes and ideally the five associated/phenocopy genes.


  • Author Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial

    by Stephen J. Nicholls, Adam J. Nelson, Marc Ditmarsch, John J. P. Kastelein, Christie M. Ballantyne, Kausik K. Ray, Ann Marie Navar, Steven E. Nissen, Anne C. Goldberg, Liam R. Brunham, et al.


  • Integration of a polygenic score into clinical risk prediction of atherosclerotic cardiovascular disease in familial hypercholesterolaemia

    by Martine Paquette, Mark Trinder, Isabelle Ruel, Simon-Pierre Guay, Robert A Hegele, Jacques Genest, Liam R Brunham, Alexis Baass

    Aims: A high polygenic risk score for coronary artery disease (PRSCAD) has been demonstrated to be a strong and independent predictor of atherosclerotic cardiovascular disease (ASCVD) in patients with familial hypercholesterolaemia (FH). The objective was to investigate if the addition of a PRSCAD to the FH-Risk-Score enhances ASCVD risk prediction compared with the clinical score alone. Methods and results: Data from three independent cohorts of patients with FH have been analysed in this longitudinal study (n = 1438). The FH-Risk-Score equation was used to calculate the baseline 10-year ASCVD risk. A high PRSCAD was defined as a score >75th percentile. The performance of the Combined score was assessed using measures of discrimination (C statistics), calibration (predicted risk vs. observed risk), and reclassification (using a 10-year risk cutoff of 20%). Overall, the event rate was nearly doubled in individuals having a high PRSCAD [15 vs. 9%, hazard ratio (HR) 1.77, 95% confidence interval (CI) 1.20–2.61, P = 0.004]. This association was stronger in those with a genetic confirmation of FH (17 vs. 8%, HR 2.34, 95% CI 1.50–3.67, P = 0.0002). The Combined score was associated with a marginally non-significant higher C-index than the FH-Risk-Score alone (0.746–0.750, P = 0.60). The difference in C-index was significant in patients with a genetic confirmation of FH in the moderate FH-Risk-Score group (0.617–0.717, P = 0.05). Conclusion: Overall, the addition of polygenic information using PRSCAD percentiles to the FH-Risk-Score estimate did not significantly enhance ASCVD risk prediction in patients with FH. Replication efforts with larger number of individuals and incident cases are warranted.